ARTICLE | Clinical News
Piromelatine: Phase II data
February 25, 2013 8:00 AM UTC
Top-line data from a double-blind, U.S. Phase II trial in 120 patients with primary insomnia showed that once-daily 20 and 50 mg doses of piromelatine for 4 weeks each met the secondary endpoint of im...